These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36989193)

  • 1. Safety of baclofen versus tizanidine for older adults with musculoskeletal pain.
    Su Zhang VR; Niu F; Lee EA; DiStasio C; Broder BI; Steinberg SG; Hui RL
    J Am Geriatr Soc; 2023 Aug; 71(8):2579-2584. PubMed ID: 36989193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baclofen and the risk of fall and fracture in older adults: A real-world cohort study.
    Hwang YJ; Chang AR; Brotman DJ; Inker LA; Grams ME; Shin JI
    J Am Geriatr Soc; 2024 Jan; 72(1):91-101. PubMed ID: 37933734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
    Chou R; Peterson K; Helfand M
    J Pain Symptom Manage; 2004 Aug; 28(2):140-75. PubMed ID: 15276195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.
    Killam-Worrall L; Brand R; Castro JR; Patel DS; Huynh K; Lindley B; Torres BP
    Ann Pharmacother; 2024 May; 58(5):523-532. PubMed ID: 37589096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study.
    Hwang YJ; Chang AR; Brotman DJ; Inker LA; Grams ME; Shin JI
    Mayo Clin Proc; 2023 May; 98(5):676-688. PubMed ID: 37028980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
    Borrini L; Bensmail D; Thiebaut JB; Hugeron C; Rech C; Jourdan C
    Arch Phys Med Rehabil; 2014 Jun; 95(6):1032-8. PubMed ID: 24407102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence associated with oral medications in the treatment of spasticity.
    Halpern R; Gillard P; Graham GD; Varon SF; Zorowitz RD
    PM R; 2013 Sep; 5(9):747-56. PubMed ID: 23648652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature.
    Karol DE; Muzyk AJ; Preud'homme XA
    Gen Hosp Psychiatry; 2011; 33(1):84.e1-2. PubMed ID: 21353141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute intrathecal baclofen withdrawal: a brief review of treatment options.
    Ross JC; Cook AM; Stewart GL; Fahy BG
    Neurocrit Care; 2011 Feb; 14(1):103-8. PubMed ID: 20717751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
    Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
    Beard S; Hunn A; Wight J
    Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.